Recent advances in the treatment of rheumatoid arthritis

Tina D. Mahajan, Ted R Mikuls

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose of review: Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. Recent findings: There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017. In aggregate, the sarilumab studies show that it is effective in RA, including patients with incomplete responses to methotrexate and anti-tumor necrosis factor inhibitor, and showing superior efficacy when used in higher dose (200 mg every 2 weeks) to standard-dose adalilumab. Other drugs that are currently being studied include the IL-6 cytokine blocker sarikumab, the small targeted molecule filgotinib, and many new biosimilars. Baracitinib failed to achieve approval by the Food and Drug Administration primarily over perceived safety concerns. The two biosimilar drugs currently approved are CT-P13 and SB2, which are based on the reference product infliximab. Although this review summarizes trials examining biologic tapering, additional data are needed to guide clinicians in regards to treatment de-escalation in RA. Summary: With the greatly expanded armamentarium of RA treatment options available, it is important for clinicians to understand the data regarding drug efficacy and safety. With remission increasingly attainable, effective drug tapering strategies are needed. Although tapering trials do exist, more studies will be needed to help guide clinical practice.

Original languageEnglish (US)
Pages (from-to)231-237
Number of pages7
JournalCurrent Opinion in Rheumatology
Volume30
Issue number3
DOIs
StatePublished - May 1 2018

Fingerprint

Biosimilar Pharmaceuticals
Rheumatoid Arthritis
Pharmaceutical Preparations
Safety
Therapeutics
Interleukin-6 Receptors
United States Food and Drug Administration
Methotrexate
Interleukin-6
Tumor Necrosis Factor-alpha
Cytokines

Keywords

  • biosimilars
  • rheumatoid arthritis
  • sarilumab
  • tapering
  • treatment

ASJC Scopus subject areas

  • Rheumatology

Cite this

Recent advances in the treatment of rheumatoid arthritis. / Mahajan, Tina D.; Mikuls, Ted R.

In: Current Opinion in Rheumatology, Vol. 30, No. 3, 01.05.2018, p. 231-237.

Research output: Contribution to journalReview article

@article{75e9c6b422dc4fbd8eaba88d8d598d8b,
title = "Recent advances in the treatment of rheumatoid arthritis",
abstract = "Purpose of review: Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. Recent findings: There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017. In aggregate, the sarilumab studies show that it is effective in RA, including patients with incomplete responses to methotrexate and anti-tumor necrosis factor inhibitor, and showing superior efficacy when used in higher dose (200 mg every 2 weeks) to standard-dose adalilumab. Other drugs that are currently being studied include the IL-6 cytokine blocker sarikumab, the small targeted molecule filgotinib, and many new biosimilars. Baracitinib failed to achieve approval by the Food and Drug Administration primarily over perceived safety concerns. The two biosimilar drugs currently approved are CT-P13 and SB2, which are based on the reference product infliximab. Although this review summarizes trials examining biologic tapering, additional data are needed to guide clinicians in regards to treatment de-escalation in RA. Summary: With the greatly expanded armamentarium of RA treatment options available, it is important for clinicians to understand the data regarding drug efficacy and safety. With remission increasingly attainable, effective drug tapering strategies are needed. Although tapering trials do exist, more studies will be needed to help guide clinical practice.",
keywords = "biosimilars, rheumatoid arthritis, sarilumab, tapering, treatment",
author = "Mahajan, {Tina D.} and Mikuls, {Ted R}",
year = "2018",
month = "5",
day = "1",
doi = "10.1097/BOR.0000000000000496",
language = "English (US)",
volume = "30",
pages = "231--237",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Recent advances in the treatment of rheumatoid arthritis

AU - Mahajan, Tina D.

AU - Mikuls, Ted R

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Purpose of review: Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. Recent findings: There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017. In aggregate, the sarilumab studies show that it is effective in RA, including patients with incomplete responses to methotrexate and anti-tumor necrosis factor inhibitor, and showing superior efficacy when used in higher dose (200 mg every 2 weeks) to standard-dose adalilumab. Other drugs that are currently being studied include the IL-6 cytokine blocker sarikumab, the small targeted molecule filgotinib, and many new biosimilars. Baracitinib failed to achieve approval by the Food and Drug Administration primarily over perceived safety concerns. The two biosimilar drugs currently approved are CT-P13 and SB2, which are based on the reference product infliximab. Although this review summarizes trials examining biologic tapering, additional data are needed to guide clinicians in regards to treatment de-escalation in RA. Summary: With the greatly expanded armamentarium of RA treatment options available, it is important for clinicians to understand the data regarding drug efficacy and safety. With remission increasingly attainable, effective drug tapering strategies are needed. Although tapering trials do exist, more studies will be needed to help guide clinical practice.

AB - Purpose of review: Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. Recent findings: There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017. In aggregate, the sarilumab studies show that it is effective in RA, including patients with incomplete responses to methotrexate and anti-tumor necrosis factor inhibitor, and showing superior efficacy when used in higher dose (200 mg every 2 weeks) to standard-dose adalilumab. Other drugs that are currently being studied include the IL-6 cytokine blocker sarikumab, the small targeted molecule filgotinib, and many new biosimilars. Baracitinib failed to achieve approval by the Food and Drug Administration primarily over perceived safety concerns. The two biosimilar drugs currently approved are CT-P13 and SB2, which are based on the reference product infliximab. Although this review summarizes trials examining biologic tapering, additional data are needed to guide clinicians in regards to treatment de-escalation in RA. Summary: With the greatly expanded armamentarium of RA treatment options available, it is important for clinicians to understand the data regarding drug efficacy and safety. With remission increasingly attainable, effective drug tapering strategies are needed. Although tapering trials do exist, more studies will be needed to help guide clinical practice.

KW - biosimilars

KW - rheumatoid arthritis

KW - sarilumab

KW - tapering

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85045219816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045219816&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000496

DO - 10.1097/BOR.0000000000000496

M3 - Review article

VL - 30

SP - 231

EP - 237

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 3

ER -